Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | SCN4A | P35499 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etifenin SCHEMBL10643382 | 0.98 | ALOX15 (0.97) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| Etifenin SCHEMBL10643374 | 0.92 | ALOX15 (0.84) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL9318396 | 0.89 | ALOX15 (0.81) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL11130240 | 0.87 | TSHR (0.77) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL9972480 | 0.86 | ALOX15 (0.76) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL11154960 | 0.83 | ALOX15 (0.70) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| Lidofenin SCHEMBL214472 | 0.82 | MAPT (0.73) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL16520404 | 0.82 | ALOX15 (0.68) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| Lidofenin SCHEMBL28279278 | 0.81 | MAPT (0.71) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| Lidofenin SCHEMBL29765217 | 0.81 | MAPT (0.71) | ALOX15TSHRCYP2C19HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| US-20230201386-A1 | PRODUCING RADIOPHARMACEUTICAL COLD KITS WITHOUT LYOPHILIZATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2023-06-29 | — | — | US | claimed |
| CN-105572251-A | Determination method of tin content in drugs | JIANGSU INST NUCLEAR MEDICINE | 2016-05-11 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-9000036-B2 | Compositions and methods for targeting of treating neoplasms | Yu, Baofa (US) | 2015-04-07 | — | — | US | claimed |
| US-20140037695-A1 | COMPOSITIONS AND METHODS FOR TARGETING OF TREATING NEOPLASMS | YU, BAOFA | 2014-02-06 | — | — | US | claimed |
| CN-103393543-A | Method using 3D printing technology to prepare dropping pills | WEI XUEWEN | 2013-11-20 | — | — | CN | claimed |
| US-8501243-B2 | Targeting cancer therapy combination | YU, BAOFA | 2013-08-06 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1264310-A | Polymer based pharmaceutical compositions for targeted delivery of biologically active agents | SDG INC (US) | 2000-08-23 | — | — | CN | claimed |
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0165728-B1 | NMR CONTRAST AGENTS | NYCOMED AS (NO) | 1988-12-14 | — | — | EP | claimed |
| US-4714607-A | NUCLEAR MAGNETIC RESONANCE | NYCOMED AS (NO) | 1987-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | ALOX15 414/4885TSHR 161/4885CYP2C19 1129/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | ALOX15 3077/4885TSHR 367/4885CYP2C19 3506/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | ALOX15 4533/4885TSHR 262/4885CYP2C19 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.